FDA recall, , Moderate risk
Lupin Pharmaceuticals Glucagon Emergency Kit for Low Blood Sugar
CGMP deviation: OOS result observed for the Gliding Force functionality test during 12-month long term stability testing.
Summary by Recall Canary from the FDA notice
What happened
Lupin Pharmaceuticals Inc., of Naples, Florida, recalled 64,894 units of its Glucagon Emergency Kit for Low Blood Sugar, Glucagon for Injection USP, 1mg per vial, Diluent for Glucagon, 1 mL syringe, Rx only, nationwide within the U.S. The recall began June 23, 2026, and was added to the FDA's Enforcement Report on July 1, 2026. The agency cited a CGMP deviation: an out-of-specification result observed for the Gliding Force functionality test during 12-month long term stability testing.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is your kit affected?
Match the NDC and lot code listed under your product.
An NDC (National Drug Code) is usually printed on the drug's label.
Glucagon Emergency Kit for Low Blood Sugar
- NDC
- 70748-311-01
- Lot code
- WB00010
- WB00017
- WB00019
- WB00070
- WB00077
- WB00078
- WB00130
Recall details
- Company began the recall
- Sold in
Nationwide within the U.S.
- Company
- Lupin Pharmaceuticals Inc.Naples, Florida
- Hazard
- Quality testing problem
- Risk
Moderate risk
Taking it may cause short-term health problems, or ones that treatment can reverse. Serious harm is unlikely.
FDA Class II recall · How risk is rated
- Event ID
- 99296
- Recall number
- D-0723-2026
- Quantity recalled
- 64,894 units
All recalls from Lupin Pharmaceuticals Inc.
Timeline
FDA's Enforcement Report is its public list of recalls; FDA adds a recall when it posts it and publishes the list weekly.
Company began the recall
Added to FDA's Enforcement Report
Listed on Recall Canary
In FDA's weekly enforcement report
Classified by FDA
Summary updated
